Spark Newswire Spark Newswire
  • Newswire
  • News
    • Guidance
    • Dividends
    • M&A
    • Buybacks
    • Legal
    • Interviews
    • Management
    • Offerings
    • IPOs
    • Insider Trades
    • Biotech/FDA
    • Tech
  • Markets
    • After Hours
    • Movers
    • ETFs
    • Forex
    • Commodities
    • Options
    • Binary Options
    • Bonds
    • Futures
    • Global Economics
    • Reviews
    • Small-Cap
    • Cryptocurrency
    • Penny Stocks
  • Analysts
    • Analyst Color
    • Analyst Ratings
    • Upgrades
    • Downgrades
  • Earnings
    • Earnings
  • Support & Feedback
  • Registration Options
  • Log In
News by Category
  • After-Hours Center
  • Analyst Color
  • Analyst Ratings
  • Asia
  • Asset Sales
  • Binary Options
  • Biotech
  • Bonds
  • Broad U.S. Equity ETFs
  • Buybacks
  • Cannabis
  • Commodities
  • Contracts
  • Crowdsourcing
  • Cryptocurrency
  • Currency ETFs
  • Dividends
  • Downgrades
  • Earnings
  • Earnings Beats
  • Earnings Misses
  • Econ #s
  • Economics
  • Education
  • Emerging Market ETFs
  • Emerging Markets
  • Entertainment
  • Entrepreneurship
  • Equities
  • ESG
  • ETFs
  • Eurozone
  • Events
  • Exclusives
  • FDA
  • Federal Reserve
  • Financial Advisors
  • Financing
  • Fintech
  • Forex
  • Futures
  • Gaming
  • General
  • Global
  • Government
  • Guidance
  • Health Care
  • Hedge Funds
  • Hot
  • Initiation
  • Insider Trades
  • Insurance
  • Interview
  • Intraday Update
  • IPOs
  • Large Cap
  • Latin America
  • Legal
  • Long Ideas
  • M&A
  • Macro Economic Events
  • Management
  • Market Summary
  • Market-Moving Exclusives
  • Markets
  • Media
  • Mid Cap
  • Movers
  • Movers & Shakers
  • Mutual Funds
  • New ETFs
  • News
  • Offerings
  • Opinion
  • Options
  • Penny Stocks
  • Personal Finance
  • Politics
  • Pre-Market Outlook
  • Press Releases
  • Previews
  • Price Target
  • Psychedelics
  • Psychology
  • Real Estate
  • Regulations
  • REIT
  • Reiteration
  • Restaurants
  • Retail Sales
  • Reviews
  • Rumors
  • SEC
  • Sector ETFs
  • Short Ideas
  • Short Sellers
  • Signals
  • Small Business
  • Small Cap
  • Small Cap Analysis
  • Small-Cap
  • Social Media
  • SPACE
  • Specialty ETFs
  • Sports
  • Sports Betting
  • Startups
  • Stock Split
  • Success Stories
  • Tech
  • Technicals
  • Termination
  • Top Stories
  • Topics
  • Trading Ideas
  • Travel
  • Treasuries
  • Uncategorized
  • Upgrades
Spark Newswire Spark Newswire
Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.
  • Newswire
  • News
    • Guidance
    • Dividends
    • M&A
    • Buybacks
    • Legal
    • Interviews
    • Management
    • Offerings
    • IPOs
    • Insider Trades
    • Biotech/FDA
    • Tech
  • Markets
    • After Hours
    • Movers
    • ETFs
    • Forex
    • Commodities
    • Options
    • Binary Options
    • Bonds
    • Futures
    • Global Economics
    • Reviews
    • Small-Cap
    • Cryptocurrency
    • Penny Stocks
  • Analysts
    • Analyst Color
    • Analyst Ratings
    • Upgrades
    • Downgrades
  • Earnings
    • Earnings
  • Support & Feedback
  • Registration Options
  • Log In
Spark Newswire Spark Newswire
Filter By Ticker
Search By Date To
Today | Yesterday | This week

Feed Symbols: BNTX

Group By Ticker
Sort By
Newest | Oldest
Read More
1 minute read
  • News

European Medicines Agency Official Says We Need To Prepare For New Wave Of Covid-19 Infections In Line With Seasonal Trend Over Past Two Years

By Benzinga Newsdesk
Today, 2:21 AM
- Reuters 

AZN

Read More
1 minute read
  • Markets
  • Movers
  • News
  • Penny Stocks
  • Pre-Market Outlook
  • Small Cap
  • Trading Ideas

Nikola, Super Micro Computer And Other Big Losers From Monday

By Lisa Levin
Today, 2:21 AM
U.S. stocks closed higher with the Dow Jones gaining around 197 points on Monday. Here is the list of some big stocks recording losses in the previous session.

BLUE

Read More
2 minute read
  • Markets
  • Options

Check Out What Whales Are Doing With BNTX

By Benzinga Insights
Today, 2:21 AM
Someone with a lot of money to spend has taken a bullish stance on BioNTech (NASDAQ:BNTX). And retail traders should know. We noticed this today when the big position showed up on publicly available options history that we track here at Benzinga.

BNTX

Read More
1 minute read
  • Movers
  • Trading Ideas

Why BioNTech, Moderna And Novavax Shares Are Diving

By Henry Khederian
Today, 2:21 AM
BioNTech SE - ADR (NASDAQ: BNTX), Moderna Inc (NASDAQ: MRNA) and Novavax, Inc. (NASDAQ: NVAX) are all trading lower during Mo

BNTX

Read More
1 minute read
  • Biotech
  • General
  • Health Care
  • Large Cap
  • News

Pfizer Starts Pivotal Phase 3 Study of mRNA-Based Influenza Vaccine

By Vandana Singh
Today, 2:21 AM
Pfizer Inc (NYSE:PFE) has dosed the first participants in the Phase 3 trial of its quadrivalent modified RNA (modRNA) influenza vaccine…

BNTX

Read More
4 minute read
  • Biotech
  • FDA
  • General
  • Health Care
  • News
  • Penny Stocks
  • Small Cap

Important Biotech Catalysts For September 12, 2022 – End Of The Day Summary

By Ragothaman Srinivasan
Today, 2:21 AM
The U.S. Food and Drug Administration (FDA) has granted Fast Track designation to Mersana Therapeutics’ (NASDAQ:MRSN) lead candidate…

ACAD

Read More
1 minute read
  • Biotech
  • General
  • News

CMS Says Updated Covid-19 Vaccines Providing Protection Against Omicron Variant Available At No Cost

By Benzinga Newsdesk
Today, 2:21 AM
- Reuters

AZN

Read More
3 minute read
  • Biotech
  • FDA
  • General
  • Health Care
  • News
  • Penny Stocks
  • Small Cap

Important Biotech Catalysts For September 9, 2022 – End Of The Day Summary

By Ragothaman Srinivasan
Today, 2:21 AM
The U.S. Food and Drug Administration (FDA) has approved Spectrum Pharmaceuticals’ (NASDAQ:SPPI) lead asset ROLVEDON (eflapegrastim-xnst) injection to…

ADAP

Read More
1 minute read
  • Biotech
  • FDA
  • General
  • News

Health Canada Authorizes Pfizer-Biontech Covid-19 Vaccine For Children Six Months To Four Years Of Age

By Benzinga Newsdesk
Today, 2:21 AM
- Reuters

BNTX

Read More
4 minute read
  • Biotech
  • FDA
  • General
  • News

BioNTech Presents Phase 1/2 Follow-Up Data For CAR-T Candidate BNT211 In Hard-To-Treat Solid Tumors At European Society for Medical Oncology

By Benzinga Newsdesk
Today, 2:21 AM
Follow-up data further demonstrate encouraging signs of clinical anti-tumor activity and a manageable safety and tolerability profile, building on the positive interim data presented at AACR in April Strongest

BNTX

Posts navigation

Previous 1 … 9 10 11 … 92 Next
Free Newsletter subscribe

Stock Market Ideas & Analysis

Stay up-to-date with the same information professionals use.
Spark Newswire Spark Newswire
  • Newswire
  • Registration
  • Log In
  • Settings
  • Privacy Policy
  • Terms of Service
© 2021 Spark Newswire
All Rights Reserved.

All news is property of their respective owners. Terms of Service